A study from the University of Michigan Health Rogel Cancer Center furthers research that suggests the potential of developing new cancer treatments to target oncogenic transcription factors by indirectly affecting their ability to access enhancer DNA in chromatin.

Using a chip to process blood samples, doctors can monitor the amount of cancer cells in a patient’s blood to determine how well a treatment is working by the fourth week, according to a new study.

If patients are trained to advocate for themselves and voice their opinions and concerns, they can mitigate the effects of providers’ implicit biases.

Menthol cigarettes were responsible for an estimated 377,000 premature deaths in the U.S. during the past 40 years.

Researchers will work to find alternative treatments for non-small cell lung cancers that have become resistant to standard treatment

By raising awareness about the correlation between increased radiation exposure and cardiac events, average doses were reduced without minimizing cancer treatment. 

Stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models.

A Rogel Cancer Center lung doctor discusses recommendations that annual screenings start at age 50 for current and former smokers with 20 “pack years”.

A 600-patient randomized clinical trial supports pembrolizumab and chemotherapy as a first-line treatment

One patient overcomes treatment fears and signs on for clinical research.

Interventional pulmonology, a relatively new medical subspecialty, is changing the way doctors diagnose and treat lung and airway conditions, including lung cancer.

False notions about the disease can prompt an unsympathetic reaction from others and shame a patient. Shift the conversation with these positive strategies.

A new tool that takes into account personalized risks and benefits, and allows for a range of patient preferences, will help clinicians decide whom to screen for lung cancer.

The USPSTF recommends lung cancer screening for people ages 55 to 80 who have smoked the equivalent of a pack a day for 30 years.

A large randomized trial finds Keytruda given with chemotherapy resulted in 20 percent improved survival at one year.